AIM Vaccine (HKG:6660) received the US Food and Drug Administration approval for clinical trials of its mRNA herpes zoster vaccine, according to a Sunday filing with the Hong Kong bourse.
Preclinical studies demonstrated that AIM's vaccine immune response significantly outperformed that of existing commercial recombinant subunit vaccines.
The drugmaker's shares were up by almost 8% in recent trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.